This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 228,774 trials Clear all
Filter by:

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Isc...
    Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Isc...
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Minocyclin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Minocyclin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Southern California Department of Neurosurgery, Los Angeles, California, United States

Brief Summary

Previous work has demonstrated patients presenting with ruptured aneurysms that develop radiographic and clinical vasospasm have a higher permeability of the blood brain membrane. Matrix metalloproteinase 9 (MMP9) has been studied and recently implicated in both the pathogenesis of the blood brain barrier breakdown and vasogenic edema of ischemia strokes, and is suggested to be an accurate biomarker to predict the onset of cerebral vasospasm after subarachnoid hemorrhage. The therapeutic benefit of minocycline, an MMP9 inhibitor, has been investigated in ischemic stroke population, however its role in the treatment of cerebral vasospasm from ruptured aneurysms remains unknown. Our project has two main goals: to further confirm MMP9 has a reliable biomarker for the onset of cerebral vasospasm, and secondarily to investigate any possible therapeutic benefit that minocycline has in the vasospasm population. Vasospasm continues to be one of the major contributors of morbidity and mortality in the ruptured aneurysm population, and close monitoring of the neurologic exam during the 'vasospasm window' usually requires two weeks in the intensive care unit in most academic settings. As such, if we are better able to predict which patients are at risk of developing vasospasm based on MMP9 levels, we will be better able to anticipate the need for intervention and therefore mitigate the risk of vasospasm induced ischemic strokes, ultimately resulting in better outcomes in the ruptured aneurysm population. Further, if we are able to identify minocycline as a therapeutic agent to deter, or lessen the severity of vasospasm, we can possibly improve neurologic outcomes, decrease hospital stays, ultimately providing an improved and more cost-effective treatment strategy to our patients.

ONO-7913 Phase I Study (ONO-7913)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Solid Tumor
    Solid Tumor
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: ONO-7913

Eligibility
  • Ages: 20 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: ONO-7913

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Local Institution, Chuo-ku, Tokyo, Japan

Brief Summary

To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Smoking Cessation
    Smoking Cessation
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Zonisamide, Drug: Bupropion, Other: Halo G6 e-cigarette

Eligibility
  • Ages: 21 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: Zonisamide, Drug: Bupropion, Other: Halo G6 e-cigarette

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Rose Research Center, Charlotte, North Carolina, United States

Brief Summary

This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline data on use of combustible cigarettes. Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in addition to continued use of the G6. At each visit, participants will receive enough zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6 and combination zonisamide and bupropion use will continue until the participant returns for the End-of-Study visit (V7).

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Danderyd Hospital, Danderyd, Sweden

Brief Summary

There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness. Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID-19. However, data is limited to small studies and case series on severely ill patients. The proposed study assesses the safety and efficacy earlier in the course of illness, in slightly less severe patients with the possibility of detecting less severe adverse events and the potential for early treatment to hinder the development of severe disease. Plasma is collected from consenting donors who have recovered from SARS-CoV-2.

A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands in Participants Age 35 and Older

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Skin Depressions, Skin Elasticity, Skin Laxity
    Skin Depressions, Skin Elasticity, Skin Laxity
  • Phase Phase 4
    Phase 4
INTERVENTION

Device: Juvéderm® VOLIFT with Lidocaine

Eligibility
  • Ages: 35 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: Juvéderm® VOLIFT with Lidocaine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Eurofins Pharmascan /ID# 233683, Lyon, France

Brief Summary

This study will evaluate the effect of Juvederm Volift with Lidocaine, an injectable gel implant, to treat aging hands of participants 35 and older.

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of placebo at the schedule of day 0,28, Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Eligibility
  • Ages: 60 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Biological: Two doses of placebo at the schedule of day 0,28, Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China

Brief Summary

This study is a randomized, double-blinded, and placebo controlled phase 1&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy elderly aged 60 years and above.

Ultrasound-guided PRP Versus Steroid Injections in Management of Carpal Tunnel Syndrome

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Carpal Tunnel Syndrome
    Carpal Tunnel Syndrome
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: platlet rich plasma (PRP), Drug: Triamcinolone Acetonide, Drug: Saline

Eligibility
  • Ages: 20 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: platlet rich plasma (PRP), Drug: Triamcinolone Acetonide, Drug: Saline

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tanta University Hospital, Tanta, Egypt

Brief Summary

Patients will be randomly divided into 3 equal groups: Group I received ultrasound guided injection of 2 mL PRP into the affected carpal tunnel. Group II received ultrasound guided injection of 2 mL steroids (40 mg triamcinolone acetonide). Group III received ultrasound guided injection of 2 mL saline as placebo control.

An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition COVID-19
    COVID-19
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: Favipiravir, Drug: Standard of Care

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Favipiravir, Drug: Standard of Care

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Republican Clinical Hospital, Makhachkala, Russian Federation

Brief Summary

The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to study during the pivotal stage. The objective of the pivotal stage is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.

A Pharmacokinetics and Safety Study of Narfurine Hydrochloride Orally Disintegrating Tablets

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Improvement of Pruritus in Hemodialysis Patients
    Improvement of Pruritus in Hemodialysis Patients
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: narfurine hydrochloride orally disintegrating tablets

Eligibility
  • Ages: 18 to 40 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: narfurine hydrochloride orally disintegrating tablets

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The First Affiliated Hospital,ZheJiang Univercity, Hanzhou, Zhejiang, China

Brief Summary

Main objective: To evaluate the pharmacokinetics of single and multiple oral administration of narfurine hydrochloride orally disintegrating tablets in Chinese healthy adult subjects. Secondary objective: To evaluate the safety profile of single and multiple oral administration of narfurine hydrochloride orally disintegrating tablets in Chinese healthy adult subjects.

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Colorectal Cancer Stage IV
    Colorectal Cancer Stage IV
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Panitumumab, Drug: Panitumumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Panitumumab, Drug: Panitumumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy

Brief Summary

The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients. Correlative studies on tumor and blood samples could identify potential biomarkers of efficacy and help defining personalized treatment strategy.